Group One Trading’s Gain Therapeutics GANX Stock Holding History

Group One Trading’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.4K	Sell	6,404 -47,755	-88%	-$104K	﹤0.01%	6243
2025 Q4	$174K	Buy	54,159 +37,384	+223%	+$99.8K	﹤0.01%	4502
2025 Q3	$29.7K	Buy	16,775 +10,374	+162%	+$17.5K	﹤0.01%	6379
2025 Q2	$11.5K	Buy	+6,401	New	+$11.8K	﹤0.01%	6628
2024 Q4	–	Sell	-1,401	Closed	-$2.81K	–	7489
2024 Q3	$2.49K	Sell	1,401 -6,000	-81%	-$7.54K	﹤0.01%	6090
2024 Q2	$9.47K	Buy	7,401 +5,400	+270%	+$14K	﹤0.01%	5673
2024 Q1	$7.54K	Sell	2,001 -1,936	-49%	-$8.03K	﹤0.01%	6009
2023 Q4	$12.9K	Buy	3,937 +2,000	+103%	+$5.56K	﹤0.01%	6045
2023 Q3	$6.26K	Buy	1,937 +1,090	+129%	+$4.13K	﹤0.01%	6580
2023 Q2	$3.79K	Buy	+847	New	+$4.13K	﹤0.01%	6836

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Group One Trading's GANX Position: Q1 2026 in Review

Group One Trading reduced its Gain Therapeutics (GANX) stake by 88% in Q1 2026, selling an estimated $104K and leaving 6,404 shares worth $12.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6243.

Group One Trading first reported a position in GANX in Q2 2023 and has held it in 10 quarters since. The position peaked at $174K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Group One Trading held 6,404 shares of Gain Therapeutics worth $12.4K as of Q1 2026.
Group One Trading sold 47,755 Gain Therapeutics shares in Q1 2026, an estimated $104K.
Gain Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6243 holding.
Group One Trading first reported a position in Gain Therapeutics in Q2 2023 and has held it in 10 quarters since.
Group One Trading's Gain Therapeutics position peaked at $174K in Q4 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.